Azitra Inc. AZTR 深 沪
已收盘 08-21 16:00:00 美东时间
0.1328
+0.006
+4.81%
华盛通- 最 高0.1405
- 今 开0.135
- 成交量 200.03万股
- 最 低 0.13
- 昨 收 0.1267
- 总市值 804.82万
- 52周最高 1.09
- 市盈率 静 --
- 换手率 3.30%
- 52周最低 0.10
- 委 比 -4.76%
- 总股本 6060.37万
- 历史最高 1034.964
- 量 比 2.69
- 振 幅 8.29%
- 历史最低 0.10
- 每 手 1
- 风险率 0.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Azitra Regains NYSE American Compliance
Azitra, Inc. ("Azitra" or the "Company") (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today announced that it has received written notification from NYSE American LLC ("NYSE...
08-21 20:02
Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards
BRANFORD, Conn., Aug. 21, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative the...
08-21 20:00
Azitra Reports Results From Two Ex Vivo Human Skin Tissue Studies Evaluating Distribution And Anti-Wrinkle Activity Of Filaggrin Domain Supernatant
ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin ("rHDfilaggrin"). This S. epidermis derived supernatant is in development as a high value cosmetic ingredient Ex vivo data successfully showed controlled distribution of the rHDfilag...
07-16 04:24
Why Sagtec Global Shares Are Trading Higher By Around 76%; Here Are 20 Stocks Moving Premarket
Shares of SAGTEC GLOBAL Ltd (NASDAQ:SAGT) gained 75.6% to $1.74 in pre-market trading after the Kuala Lumpur-based enterprise software firm issued financial year 2026 guidance projecting 35% revenue growth. Sagtec projected $25.78 million in revenue, up from $19.1 million in the financial year 2025....
06-22 17:21
Why Did Azitra (AZTR) Stock Jump Over 25% After Hours?
Azitra Inc. (NYSE:AZTR) shares soared 25.45% to $0.22 after the bell on Thursday. The surge in the stock of the Connecticut-based biopharmaceutical company in the late trading session follows an intraday decline of 15.42%, closing the regular session at $0.17, according to Benzinga Pro data. Volume ...
06-19 15:06
Azitra CEO Issues Shareholder Letter Outlining Strategic Initiatives, Recent Milestones And 2026 Outlook
Azitra, Inc. ("Azitra" or the "Company") (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Francisco Salva, Chief Executive Officer of Azitra, has issued a Letter to Shareholders detailing the Company's ...
06-17 20:08
Azitra, Inc. to Present at 2026 BIO International Convention
BRANFORD, Conn., June 16, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermato...
06-17 05:28
Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting
BRANFORD, Conn., June 4, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatol...
06-05 04:05
